Ensol Biosciences (XKRX:140610) Gross Margin % : 73.25% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Ensol Biosciences's Gross Profit for the six months ended in Dec. 2023 was ₩129.3 Mil. Ensol Biosciences's Revenue for the six months ended in Dec. 2023 was ₩176.5 Mil. Therefore, Ensol Biosciences's Gross Margin % for the quarter that ended in Dec. 2023 was 73.25%.

The historical rank and industry rank for Ensol Biosciences's Gross Margin % or its related term are showing as below:

XKRX:140610' s Gross Margin % Range Over the Past 10 Years
Min: 2.03 Med: 33.83 Max: 87
Current: 73.25

During the past 10 years, the highest Gross Margin % of Ensol Biosciences was 87.00%. The lowest was 2.03%. And the median was 33.83%.

XKRX:140610's Gross Margin % is ranked better than
65.2% of 750 companies
in the Biotechnology industry
Industry Median: 60.91 vs XKRX:140610: 73.25

Ensol Biosciences had a gross margin of 73.25% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Ensol Biosciences was 31.30% per year.

Ensol Biosciences Gross Margin % Historical Data

The historical data trend for Ensol Biosciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Gross Margin % Chart

Ensol Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

Get a 7-Day Free Trial

36.97

72.08

30.69

87.00

73.25

Ensol Biosciences Semi-Annual Data
	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
Gross Margin %	Get a 7-Day Free Trial					36.97	72.08	30.69	87.00	73.25

Competitive Comparison of Ensol Biosciences's Gross Margin %

For the Biotechnology subindustry, Ensol Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ensol Biosciences's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's Gross Margin % falls into.

Ensol Biosciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Ensol Biosciences's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	129.3	/	176.545
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(176.545 - 47.229)	/	176.545
	=	73.25 %

Ensol Biosciences's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	129.3	/	176.545
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(176.545 - 47.229)	/	176.545
	=	73.25 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Ensol Biosciences (XKRX:140610) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Ensol Biosciences had a gross margin of 73.25% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Ensol Biosciences Gross Margin % Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences (XKRX:140610) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036

Website

http://www.ensolbio.co.kr

Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines